Preprint · CC-BY
via OpenAlex
Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease
Miranda E. Orr, Valentina R. Garbarino, Juan Pablo Palavicini, Justin Melendez, Nicolas R. Barthélemy, Yingxin He, Tiffany F. Kautz, Marisa Lopez‐Cruzan, Julia Mathews, Peng Xu, Bin Zhang, Afaf Saliba, Nagarjunachary Ragi, Kumar Sharma, Suzanne Craft
Research Square · 2024 · ▲ 8 citations
Abstract
This 2024 Research Square study evaluates exploratory fluid biomarker findings from a phase 1 clinical trial of a senolytic agent in mild Alzheimer disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.21203/rs.3.rs-3994894/v1
- Canonical
- link ↗
- Fetched
- 2026-06-15 MST
Cite this
APA
Orr, M.E., Garbarino, V.R., Palavicini, J.P., Melendez, J., Barthélemy, N.R., He, Y., Kautz, T.F., Lopez‐Cruzan, M., Mathews, J., Xu, P., Zhang, B., Saliba, A., Ragi, N., Sharma, K., Craft, S., Petersen, R.C., Espíndola‐Netto, J.M., Xue, A., Tchkonia, T., & Kirkland, J.L. (2024). Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-3994894/v1
Vancouver
Orr ME, Garbarino VR, Palavicini JP, Melendez J, Barthélemy NR, He Y, et al. Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease. Research Square. 2024. doi:10.21203/rs.3.rs-3994894/v1.
BibTeX
@unpublished{miranda2024Evalua,
title = {Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease},
author = {Miranda E. Orr and Valentina R. Garbarino and Juan Pablo Palavicini and Justin Melendez and Nicolas R. Barthélemy and Yingxin He and Tiffany F. Kautz and Marisa Lopez‐Cruzan and Julia Mathews and Peng Xu and Bin Zhang and Afaf Saliba and Nagarjunachary Ragi and Kumar Sharma and Suzanne Craft and Ronald C. Petersen and Jair Machado Espíndola‐Netto and Ailing Xue and Tamar Tchkonia and James L. Kirkland and Sudha Seshadri and Arash Salardini and Nicolas Musi and Randall J. Bateman and Mitzi M. Gonzales},
journal = {Research Square},
year = {2024},
doi = {10.21203/rs.3.rs-3994894/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neurotherapeutics 2025
Open access · CC-BY
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease
Cell Death and Differentiation 2008
Citation only
Autophagy genes and ageing
Neuroscience 2006
Citation only
Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson’s disease
Nature Medicine 2024
Preprint · OA
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Neuroscience 2019
Citation only
Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease
Neuroscience Bulletin 2014
Open access · OA